|
|
|
|
|
|
|
|
|
|
| You
are encouraged to distribute the up-to-date English-language
VIS (above) at the same time as the translation. |
|
| |
|
|
|
| Translations: Out-of-date |
|
|
|
| The translations for
some VISs on our website are from previously published English-language
versions that have since been updated. Unfortunately, IAC is not always
able to obtain translations as updates are issued. Please ensure that your
patients receive information consistent with the current English-language
version of
the following VISs. |
|
| TRANSLATIONS OF THE JANUARY 15, 2003 MMR VIS |
|
| |
|
| These translations do not
contain the following CDC updates: |
|
| • |
|
Information was added about MMRV vaccine, tied to the March 14 MMWR, regarding increased risk of certain adverse events, including febrile seizures, with MMRV when compared with MMR and varicella vaccines given separately. Aside from two boxes containing information about MMRV, both VISs are identical to the previous editions. |
|
|
|
| • |
|
The new VISs should be used when MMRV is given; but the existing stocks of the individual MMR and varicella VISs may be used when the vaccines are given separately. |
|
|
|
|
| TRANSLATIONS OF THE DECEMBER 16, 1998 MMR VIS |
|
| |
|
| These translations do not
contain the following CDC updates: |
|
| • |
|
Most of the changes to
this VIS relate to the current exclusive use of the acellular DTaP; the
previous VIS included the whole-cell DTP, which is no longer used in the
U.S. |
|
|
|
| • |
|
Rates of reactions
(problems) that might be expected following DTaP have been changed and
are generally lower that those following DTP. |
|
|
|
| • |
|
The new URL for the
National Vaccine Injury Compensation Program is listed. |
|
|
| This page was reviewed on February 26, 2009 |